Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.
Company profile
Ticker
NVO, NONOF
Exchange
Website
CEO
Lars Fruergaard Joergensen
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
NVO stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
17 May 24
SD
Conflict minerals disclosure
17 May 24
6-K
Current report (foreign)
15 May 24
6-K
Current report (foreign)
13 May 24
6-K
Current report (foreign)
13 May 24
6-K
Current report (foreign)
6 May 24
6-K
Current report (foreign)
6 May 24
6-K
Current report (foreign)
6 May 24
6-K
Current report (foreign)
6 May 24
6-K
Current report (foreign)
2 May 24
Latest ownership filings
SC 13G/A
BlackRock Inc.
6 Feb 24
11-K
Annual report of employee stock purchases
27 Jun 23
11-K
Annual report of employee stock purchases
27 Jun 23
SC 13G/A
BlackRock Inc.
23 Feb 23
11-K
Annual report of employee stock purchases
28 Jun 22
11-K
Annual report of employee stock purchases
28 Jun 22
SC 13G/A
BlackRock Inc.
1 Feb 22
11-K
Annual report of employee stock purchases
23 Jun 21
11-K
Annual report of employee stock purchases
23 Jun 21
SC 13G/A
BlackRock Inc.
29 Jan 21
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2024
9.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1648 |
Opened positions | 490 |
Closed positions | 109 |
Increased positions | 592 |
Reduced positions | 393 |
13F shares | Current |
---|---|
Total value | 35.75 tn |
Total shares | 320.88 mm |
Total puts | 4.93 mm |
Total calls | 5.29 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Jennison Associates | 21.08 mm | $2.71 tn |
FMR | 17.60 mm | $2.26 tn |
Fisher Asset Management | 13.72 mm | $1.76 tn |
BAC Bank Of America | 13.05 mm | $1.68 tn |
MS Morgan Stanley | 12.01 mm | $1.54 tn |
Fayez Sarofim & Co | 11.82 mm | $1.52 tn |
Renaissance Technologies | 10.79 mm | $1.38 bn |
Loomis Sayles & Co L P | 8.85 mm | $1.14 bn |
Folketrygdfondet | 8.76 mm | $1.12 tn |
T. Rowe Price | 8.59 mm | $1.10 bn |
News
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
23 May 24
Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
22 May 24
Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
22 May 24
NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
22 May 24
Reuters Reported Novo Nordisk Site In Denmark Hit By Fire
22 May 24
Press releases
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
21 May 24
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
17 May 24
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
8 May 24
Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)
22 Apr 24
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
19 Apr 24